Envestnet Asset Management Inc. Grows Stock Position in Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Envestnet Asset Management Inc. grew its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTXGet Rating) by 75.1% during the second quarter, Holdings Channel reports. The institutional investor owned 14,124 shares of the biotechnology company’s stock after purchasing an additional 6,056 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Mirati Therapeutics were worth $948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC boosted its position in Mirati Therapeutics by 102.4% during the first quarter. Signaturefd LLC now owns 338 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 171 shares during the period. Treasurer of the State of North Carolina grew its stake in Mirati Therapeutics by 1.6% in the 1st quarter. Treasurer of the State of North Carolina now owns 15,427 shares of the biotechnology company’s stock valued at $1,268,000 after buying an additional 248 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in Mirati Therapeutics during the 2nd quarter valued at $25,000. Advisor Group Holdings Inc. lifted its position in shares of Mirati Therapeutics by 211.1% during the first quarter. Advisor Group Holdings Inc. now owns 644 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 437 shares in the last quarter. Finally, IndexIQ Advisors LLC bought a new position in shares of Mirati Therapeutics in the first quarter worth $42,000.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MRTX shares. Piper Sandler initiated coverage on Mirati Therapeutics in a research note on Thursday, September 15th. They set an “overweight” rating and a $110.00 price objective on the stock. StockNews.com assumed coverage on shares of Mirati Therapeutics in a research note on Wednesday, October 12th. They set a “sell” rating for the company. JPMorgan Chase & Co. lowered their target price on shares of Mirati Therapeutics from $109.00 to $94.00 and set an “overweight” rating on the stock in a research note on Monday, September 26th. Citigroup decreased their price target on shares of Mirati Therapeutics from $127.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, November 16th. Finally, Jonestrading assumed coverage on Mirati Therapeutics in a research note on Tuesday, September 13th. They set a “buy” rating and a $100.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.64.

Mirati Therapeutics Trading Up 11.3 %

Shares of NASDAQ MRTX opened at $95.85 on Friday. The stock’s 50-day moving average is $70.07 and its 200 day moving average is $67.95. The stock has a market cap of $5.52 billion, a price-to-earnings ratio of -7.16 and a beta of 0.84. Mirati Therapeutics, Inc. has a 1-year low of $32.96 and a 1-year high of $154.17.

About Mirati Therapeutics

(Get Rating)

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.

Featured Stories

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics, Inc. (NASDAQ:MRTXGet Rating).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.